Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 14 drugs with upcoming expirations

Activity

Recent Activity

Last 14 days

Sep 18, 2026

Active, not recruiting

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications

Earlier

Aug 21, 2026TrialA Phase 2, Open-Label, Long-Term Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies in Healthy Participants Following Annual Doses of CD388, a Novel Long-Acting Antiviral Conjugate

Aug 20, 2026TrialA Phase 1, Double-blind, Randomized Trial to Evaluate Safety and Immunogenicity of Fluzone® High-Dose Influenza Vaccine When Concomitantly Administered With CD388, a Novel Long-Acting Antiviral Conjugate for the Prevention of Influenza

Jul 14, 2026FDALipfendra — LIPFENDRA

Jun 15, 2026FDAEmend — APREPITANT

Jun 12, 2026FDAWelireg — WELIREG

Jan 21, 2026FDAVerquvo — VERQUVO

Oct 29, 2025FDAPifeltro — PIFELTRO

3 more events

May 14, 2025FDAWelireg — WELIREG

Apr 15, 2025FDAWelireg — WELIREG

Details

Company Info

Regulatory

Regulatory Timeline

20238 events

FDADec 14

Welireg — WELIREG

Application NDA215383

FDASep 14

Temodar — TEMODAR

Application NDA022277

FDASep 14

Temodar — TEMODAR

Application NDA021029

FDASep 14

Temodar — TEMODAR

Application NDA021029

FDASep 14

Temodar — TEMODAR

Application NDA022277

FDASep 14

Temodar — TEMODAR

Application NDA022277

FDASep 14

Temodar — TEMODAR

Application NDA021029

FDAMay 10

Verquvo — VERQUVO

Application NDA214377

20244 events

FDANov 7

Pifeltro — PIFELTRO

Application NDA210806

FDAAug 30

Prevymis — PREVYMIS

Application NDA219104 (NDA)

FDAJun 26

Ohtuvayre — OHTUVAYRE

Application NDA217389 (NDA)

FDAFeb 26

Welireg — WELIREG

Application NDA215383

20254 events

FDAOct 29

Pifeltro — PIFELTRO

Application NDA210806

FDAMay 14

Welireg — WELIREG

Application NDA215383

FDAApr 15

Welireg — WELIREG

Application NDA215383

FDAApr 15

Welireg — WELIREG

Application NDA215383

20264 events

FDAJul 14

Lipfendra — LIPFENDRA

Application NDA220848 (NDA)

FDAJun 15

Emend — APREPITANT

Application NDA218754 (NDA)

FDAJun 12

Welireg — WELIREG

Application NDA215383

FDAJan 21

Verquvo — VERQUVO

Application NDA214377

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)